Astaxanthin, oxidative stress, inflammation and cardiovascular disease

Future Cardiology

Volumn 5, Issue 4, 2009, Pages 333-342

  Fassett, Robert G ^a,b   Coombes, Jeff S ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antioxidants; Cardiovascular disease; Isoprostanes; Xanthophyll carotenoids

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ASTAXANTHIN; BETA CAROTENE; CANTHAXANTHIN; CAPSORUBIN; CAROTENOID; COPPER; DISODIUM DISUCCINATE ASTAXANTHIN; LIPID; LYCOPENE; PLACEBO; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VIOLAXANTHIN; XANTHOPHYLL; ZEAXANTHIN; ZINC;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD RHEOLOGY; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CAROTID ARTERY THROMBOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; LIPID PEROXIDATION; MIDDLE CEREBRAL ARTERY OCCLUSION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; ANTIOXIDANTS; BLOOD CIRCULATION; CARDIOVASCULAR DISEASES; CAROTENOIDS; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; LIPID PEROXIDATION; MUSCLE, SKELETAL; MYOCARDIUM; OXIDATIVE STRESS; XANTHOPHYLLS;

EID: 69749120073     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.09.19     Document Type: Review

References (83)

1. Dzau VJ, Antman EM, Black HR et al.: The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 114, 2871-2891 (2006).
2. Ellingsen I, Seljeflot I, Arnesen H, Tonstad S: Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: a 3-year intervention study. Nutr. Metab. Cardiovasc. Dis. 19, 8-14 (2009).
3. Carty JL, Bevan R, Waller H et al.: The effects of vitamin C supplementation on protein oxidation in healthy volunteers. Biochem. Biophys. Res. Commun. 273, 729-735 (2000).
4. Carpenter KL, Kirkpatrick PJ, Weissberg PL et al.: Oral a-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. Free Radic. Res. 37, 1235-1244 (2003).
5. Frei B: Cardiovascular disease and nutrient antioxidants: role of low-density lipoprotein oxidation. Crit. Rev. Food Sci. Nutr. 35, 83-98 (1995).
6. Steinberg D: Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation 85, 2337-2344 (1992).
7. Stampfer MJ, Hennekens CH, Manson JE et al.: Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 328, 1444-1449 (1993).
8. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett CW: Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 328, 1450-1456 (1993).
9. Gey KF, Puska P: Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann. NY Acad. Sci. 570, 268-282 (1989).
10. Willcox BJ, Curb JD, Rodriguez LB: Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am. J. Cardiol. 101, 75D-86D (2008).
11. Helmersson J, Arnlov J, Larsson A, Basu S: Low dietary intake of β-carotene, α-tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort. Br. J. Nutr. 1-8 (2008).
12. Osganian SK, Stampfer MJ, Rimm E et al.: Dietary carotenoids and risk of coronary artery disease in women. Am. J. Clin. Nutr. 77, 1390-1399 (2003).
13. Ford ES, Giles HW: Serum vitamins, carotenoids, and angina pectoris: findings from the National Health and Nutrition Examination Survey III. Ann. Epidemiol. 10, 106-116 (2000).
14. Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH et al.: Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 69, 261-266 (1999).
15. Gaziano JM, Manson JE, Branch LG et al.: A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann. Epidemiol. 5, 255-260 (1995).
16. Morris DL, Kritchevsky SB, Davis EC: Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA 272, 1439-1441 (1994).
17. Knekt P, Reunanen A, Jarvinen R et al.: Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 139, 1180-1189 (1994).
18. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381-1478 (2004).
19. Stephens NG, Parsons A, Scho?eld PM et al.: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347, 781-786 (1996).
20. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107, 992-995 (2003).
21. Boaz M, Smetana S, Weinstein T et al.: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356, 1213-1218 (2000).
22. Steinhubl SR: Why have antioxidants failed in clinical trials? Am. J. Cardiol. 101, 14D-19D (2008).
23. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 23-33 (2002).
24. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 154-160 (2000).
25. Sandmann G: Carotenoid biosynthesis in microorganisms and plants. Eur. J. Biochem. 223, 7-24 (1994).
26. McNulty H, Jacob RF, Mason PR: Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am. J. Cardiol. 101, 20D-29D (2008).
27. Jackson H, Braun CL, Ernst H: The chemistry of novel xanthophyll carotenoids. Am. J. Cardiol. 101, 50D-57D (2008).
28. McNulty HP, Byun J, Lockwood SF, Jacob RF, Mason PR: Differential effects of carotenoids on lipid peroxidation due to membrane interactions: x-ray diffraction ana lysis. Biochim. Biophys. Acta 1768, 167-174 (2007).
29. Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
30. No Authors Listed: The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. The α-Tocopherol, β Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330, 1029-1035 (1994).
31. Omenn GS, Goodman GE, Thornquist MD et al.: Effects of a combination of β carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150-1155 (1996).
32. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens HC: β-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J. Natl Cancer Inst. 91, 2102-2106 (1999).
33. Hennekens CH, Buring JE, Manson JE et al.: Lack of effect of long-term supplementation with β carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 1145-1149 (1996).
34. Burton GW, Ingold UK: β-Carotene: an unusual type of lipid antioxidant. Science 224, 569-573 (1984).
35. Lauver DA, Driscoll EM, Lucchesi RB: Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. Pharmacology 82, 67-73 (2008).
36. Gross GJ, Lockwood FS: Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Life Sci. 75, 215-224 (2004).
37. Gross GJ, Hazen SL, Lockwood FS: Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. Mol. Cell Biochem. 283, 23-30 (2006).
38. Guerin M, Huntley ME, Olaizola M: Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol. 21, 210-216 (2003).
39. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H: Astaxanthin, a carotenoid with potential in human health and nutrition. J. Nat. Prod. 69, 443-449 (2006).
40. Schweigert, F: Metabolism of carotenoids in mammals. In: Carotenoids: Isolation and Analysis. Britton G, Liaaen-Jensen S, Pfander H (Eds.). Birkhauser Verlag, Basel, Switzerland (1998).
41. Jyonouchi H, Sun S, Tomita Y, Gross DM: Astaxanthin, a carotenoid without vitamin activity A, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. J. Nutr. 125, 2483-2492 (1995).
42. Shimidzu N: Carotenoids as singlet oxygen quenchers in marine organisms. Fish. Sci. 62, 134-137 (1996).
43. Miki W: Biological functions and activities of animal carotenoids. Pure Appl. Chem. 63, 141-146 (1991).
44. Krinsky NI: Antioxidant functions of carotenoids. Free Radic. Biol. Med. 7, 617-635 (1989).
45. Beutner S, Bloedorn B, Frixel S et al.: Quantitative assessment of antioxidant properties of natural colorants and phytochemicals: carotenoids, flavonoids, phenols and indigoids. The role of β-carotene in antioxidant functions. J. Sci. Food Agric. 559-568 (2001).
46. Pashkow FJ, Watumull DG, Campbell LC: Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am. J. Cardiol. 101, 58D-68D (2008).
47. Camara B, Bouvier F: Oxidative remodeling of plastid carotenoids. Arch. Biochem. Biophys. 430, 16-21 (2004).
48. Sharoni Y, Agbaria R, Amir H et al.: Modulation of transcriptional activity by antioxidant carotenoids. Mol. Aspects Med. 24, 371-384 (2003).
49. Kobayashi M, Kakizono T, Nishio N, Nagai S, Kurimura Y, Tsuji Y: Antioxidant role of astaxanthin in the green alga Haematococcus pluvialis. Appl. Microbiol. Biotechnol. 48, 351-356 (1997).
50. Ernst H: Recent advances in industrial carotenoid synthesis. Pure Appl. Chem. 74, 2213-2226 (2002).
51. Lockwood SF, Gross JG: Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc. Drug Rev. 23, 199-216 (2005).
52. Shargel L, Yu A: Applied Biopharmaceutics and Pharmacokinetics. Appleton-Lange, Stamford CT, USA (1999).
53. Rishton GM: Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am. J. Cardiol. 101, 43D-49D (2008).
54. Lauver DA, Lockwood SF, Lucchesi RB: Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J. Pharmacol. Exp. Ther. 314, 686-692 (2005).
55. Kang JO, Kim SJ, Kim H: Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl4-treated rats. Methods Find Exp. Clin. Pharmacol. 23, 79-84 (2001).
56. Kamath BS, Srikanta BM, Dharmesh SM, Sarada R, Ravishankar AG: Ulcer preventive and antioxidative properties of astaxanthin from Haematococcus pluvialis. Eur. J. Pharmacol. 590, 387-395 (2008).
57. Naito Y, Uchiyama K, Aoi W et al.: Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors 20, 49-59 (2004).
58. Ohgami K, Shiratori K, Kotake S et al.: Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 44, 2694-2701 (2003).
59. Lee SJ, Bai SK, Lee KS et al.: Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(κ)B kinase-dependent NF-κB activation. Mol. Cells 16, 97-105 (2003).
60. Aoi W, Naìto Y, Sakuma K et al.: Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid. Redox Signal 5, 139-144 (2003).
61. Uchiyama K, Naito Y, Hasegawa G et al.: Astaxanthin protects β-cells against glucose toxicity in diabetic db/db mice. Redox Rep. 7, 290-293 (2002).
62. Nakajima Y, Inokuchi Y, Shimazawa M et al.: Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J. Pharm. Pharmacol. 60, 1365-1374 (2008).
63. Manabe E, Handa O, Naito Y et al.: Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J. Cell Biochem. 103, 1925-1937 (2008).
64. Nakano M, Onodera A, Saito E et al.: Effect of astaxanthin in combination with α-tocopherol or ascorbic acid against oxidative damage in diabetic ODS rats. J. Nutr. Sci Vitaminol (Tokyo) 54, 329-334 (2008).
65. Choi SK, Park YS, Choi DK, Chang IH: Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J. Microbiol. Biotechnol. 18, 1990-1996 (2008).
66. Liu X, Shibata T, Hisaka S, Osawa T: Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res. 1254, 18-27 (2009).
67. Iwamoto T, Hosoda K, Hirano R et al.: Inhibition of low-density lipoprotein oxidation by astaxanthin. J. Atheroscler. Thromb. 7, 216-222 (2000).
68. Gross GJ, Lockwood FS: Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol. Cell Biochem. 272, 221-227 (2005).
69. Nusca A, Mel? R, Di Sciascio G: Percutaneous coronary interventions and statins therapy. Ther. Adv. Cardiovasc. Dis. 2, 101-107 (2008).
70. Hussein G, Nakamura M, Zhao Q et al.: Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol. Pharm. Bull. 28, 47-52 (2005).
71. Hussein G, Goto H, Oda S, Sankawa U, Matsumoto K, Watanabe H: Antihypertensive potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in spontaneously hypertensive rats. Biol. Pharm. Bull. 29, 684-688 (2006).
72. Shen H, Kuo CC, Chou J et al.: Astaxanthin reduces ischemic brain injury in adult rats. FASEB J (2009).
73. Yamamoto R, Kanazawa A, Shimizu T et al.: Association between atherosclerosis and newly classified chronic kidney disease stage for Japanese patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 84, 39-45 (2009).
74. Rufer CE, Moeseneder J, Briviba K, Rechkemmer G, Bub A: Bioavailability of astaxanthin stereoisomers from wild (Oncorhynchus spp.) and aquacultured (Salmo salar) salmon in healthy men: a randomised, double-blind study. Br. J. Nutr. 99, 1048-1054 (2008).
75. Coral-Hinostroza GN, Ytrestoyl T, Ruyter B, Bjerkeng B: Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3′R/S isomers of astaxanthin fatty acyl diesters. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 139, 99-110 (2004).
76. Spiller GA, Dewell A: Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J. Med. Food. 6, 51-56 (2003).
77. Karppi J, Rissanen TH, Nyyssonen K et al.: Effects of astaxanthin supplementation on lipid peroxidation. Int. J. Vitam. Nutr. Res. 77, 3-11 (2007).
78. Andersen LP, Holck S, Kupcinskas L et al.: Gastric in?ammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. FEMS Immunol. Med. Microbiol. 50, 244-248 (2007).
79. Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S: Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology 115, 324-333 E2 (2008).
80. Miyawaki H, Takahashi J, Tsukahara H, Takehara I: Effects of astaxanthin on human blood rheology. J. Clin. Biochem. Nutr. 43, 69-74 (2008).
81. Fassett RG, Healy H, Driver R et al.: Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. BMC Nephrol. 9, 17 (2008).
82. Osterlie M, Bjerkeng B, Liaaen-Jensen S: Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. J. Nutr. Biochem. 11, 482-490 (2000).
83. Mercke Odeberg J, Lignell A, Pettersson A, Hoglund P: Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur. J. Pharm. Sci. 19, 299-304 (2003).